Probiotic Supplementation in Chronic Kidney Disease: A Double-blind, Randomized, Placebo-controlled Trial

Journal of Renal Nutrition

Volumn 28, Issue 1, 2018, Pages 28-36

  Borges, Natália A ^a   Carmo, Flávia L ^b   Stockler Pinto, Milena B ^a   de Brito, Jessyca S ^a   Dolenga, Carla J ^c   Ferreira, Dennis C ^d   Nakao, Lia S ^c   Rosado, Alexandre ^b   Fouque, Denis ^e   Mafra, Denise ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d VEIGA DE ALMEIDA UNIVERSITY   (Brazil)

^e CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4-CRESOL SULFATE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CRESOL; IL6 PROTEIN, HUMAN; INDICAN; INDOLEACETIC ACID; INDOLEACETIC ACID DERIVATIVE; INTERLEUKIN 6; PROBIOTIC AGENT; SULFATE;

ADULT; BIFIDOBACTERIUM; BLOOD; BODY MASS; CHEMISTRY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FECES; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; NUTRITIONAL ASSESSMENT; PH; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS THERMOPHILUS; WAIST CIRCUMFERENCE;

ADULT; BIFIDOBACTERIUM; BIOMARKERS; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CRESOLS; DOUBLE-BLIND METHOD; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; HYDROGEN-ION CONCENTRATION; INDICAN; INDOLEACETIC ACIDS; INTERLEUKIN-6; LACTOBACILLUS ACIDOPHILUS; MALE; MIDDLE AGED; NUTRITION ASSESSMENT; PROBIOTICS; RENAL INSUFFICIENCY, CHRONIC; STREPTOCOCCUS THERMOPHILUS; SULFURIC ACID ESTERS; WAIST CIRCUMFERENCE;

EID: 85028757443     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2017.06.010     Document Type: Article

References (47)

1. Vaziri, N.D., Wong, J., Pahl, M., et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 83 (2013), 308–315.
2. Mafra, D., Lobo, J.C., Barros, A.F., Koppe, L., Vaziri, N.D., Fouque, D., Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol 9 (2014), 399–410.
3. Montemurno, E., Cosola, C., Dalfino, G., et al. What would you like to eat, Mr CKD microbiota? A Mediterranean diet, please!. Kidney Blood Press Res 39 (2014), 114–123.
4. Rossi, M., Johnson, D.W., Campbell, K.L., The kidney-gut axis: implications for nutrition care. J Ren Nutr 25 (2015), 399–403.
5. Wong, J., Piceno, Y.M., DeSantis, T.Z., Pahl, M., Andersen, G.L., Vaziri, N.D., Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD. Am J Nephrol 39 (2014), 230–237.
6. Liabeuf, S., Drüeke, T.B., Massy, Z.A., Protein-bound uremic toxins: new insight from clinical studies. Toxins 3 (2011), 911–919.
7. Sallée, M., Dou, L., Cerini, C., Poitevin, S., Brunet, P., Burtey, S., The Aryl Hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. Toxins 6 (2014), 934–949.
8. Poesen, R., Windey, K., Neven, E., et al. The influence of CKD on colonic microbial metabolism. J Am Soc Nephrol 27 (2015), 1389–1399.
9. Hida, M., Aiba, Y., Sawamura, S., Satoh, T., Koga, Y., Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74 (1996), 349–355.
10. Takayama, F., Taki, K., Niwa, T., Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis 41 (2003), S142–S145.
11. Ranganathan, N., Patel, B.G., Ranganathan, P., et al. In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO J 52 (2006), 70–79.
12. Ranganathan, N., Ranganathan, P., Friedman, E.A., et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 27 (2010), 634–647.
13. Miranda Alatriste, P.V., Urbina Arronte, R., Gómez Espinosa, C.O., Espinosa Cuevas Mde, L., Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr Hosp 29 (2014), 582–590.
14. Natarajan, R., Pechenyak, B., Vyas, U., et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. Biomed Res Int, 2014, 2014, 568571.
15. Ramezani, A., Raj, D.S., The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 25 (2014), 657–670.
16. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada, April 30 and May 1, 2002. Available at: http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-rpt0282-tab-03-ref-19-joint-faowho-vol219.pdf. Accessed November 23, 2016.
17. O'hara, A.M., Shanahan, F., The gut flora as a forgotten organ. EMBO Rep 7 (2006), 688–693.
18. Seth, A., Yan, F., Polk, D.B., Rao, R.K., Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PCK and MAP kinase dependent mechanism. Am J Physiol Gastrointest Liver Physiol 294 (2008), 1060–1069.
19. Borges, N.A., Barros, A.F., Nakao, L.S., Dolenga, C.J., Fouque, D., Mafra, D., Protein-bound uremic toxins from gut microbiota and inflammatory markers in chronic kidney disease. J Ren Nutr 26 (2016), 396–400.
20. Meert, N., Schepers, E., Glorieux, G., et al. Novel method for simultaneous determination of p-cresylsulphate and p-cresyl glucuronide: clinical data and pathophysiological implications. Nephrol Dial Transplant 27 (2012), 2388–2396.
21. Barros, A.F., Borges, N.A., Ferreira, D.C., et al. Is there interaction between gut microbial profile and cardiovascular risk in chronic kidney disease patients?. Future Microbiol 10 (2015), 517–526.
22. Heymsfield, S.B., McManus, C., Smith, J., Stevens, V., Nixon, D.W., Anthropometric measurement of muscle mass: revised equations for calculating bone-free arm muscle area. Am J Clin Nutr 36 (1982), 680–690.
23. Reid, G., Jass, J., Sebulsky, T., McCormick, J.K., Potential uses of probiotics in clinical practice. Clin Microbiol Rev 16 (2003), 658–672.
24. Boyle, R.J., Robins-Browne, R.M., Tang, M.L.K., Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr 83 (2006), 1256–1264.
25. Snydman, D.R., The safety of probiotics. Clin Infect Dis 46 (2008), S104–S111.
26. Vaziri, N.D., Zhao, Y.Y., Pahl, M.V., Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant 31 (2015), 737–746.
27. Vaziri, N.D., CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens 21 (2012), 587–592.
28. Meijers, B.K., Bammens, B., De Moor, B., Verbeke, K., Vanrenterghem, Y., Evenepoel, P., Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 73 (2008), 1174–1180.
29. Suzuki, K., Benno, Y., Mitsuoka, T., Takebe, S., Kobashi, K., Hase, J., Urease-producing species of intestinal anaerobes and their activities. Appl Environ Microbiol 37 (1979), 379–382.
30. Cook, A.R., Urease activity in the rumen of sheep and the isolation of ureolytic bacteria. J Gen Microbiol 92 (1976), 32–48.
31. Lam, S., Yeo, M., Urease-positive vibrio parahaemolyticus strain. J Clin Microbiol 12 (1980), 57–59.
32. Orth, D., Grif, K., Dierich, M.P., Würzner, R., Prevalence, structure and expression of urease genes in Shiga toxin-producing Escherichia coli from humans and the environment. Int J Hyg Environ Health 209 (2006), 513–520.
33. Raff, H., Levitzky, M.G., Fisiologia médica: uma abordagem integrada. 2012, AMGH, Porto Alegre cap. 57, p. 579. (Lange).
34. Fallingborg, J., Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 46 (1999), 183–196.
35. Tejero-Sariñena, S., Barlowb, J., Costabile, A., Gibson, G.R., Rowland, I., In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens: evidence for the effects of organic acids. Anaerobe 18 (2012), 530–538.
36. Bull-Otterson, L., Feng, W., Kirpich, I., et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One, 8, 2013, e53028.
37. Poesen, R., Meijersjorn, B., Evenepoel, P., The colon: an overlooked site for therapeutics in dialysis patients. Semin Dial 26 (2013), 323–332.
38. Hayes, C.P. Jr., McLeod, M.E., Robinson, R.R., An extrarenal mechanism for the maintenance of potassium balance in severe chronic renal failure. Trans Assoc Am Physicians 80 (1967), 207–216.
39. Mathialahan, T., Maclennan, K.A., Sandle, L.N., Verbeke, C., Sandle, G.I., Enhanced large intestinal potassium permeability in end-stage renal disease. J Pathol 206 (2005), 46–51.
40. Vaziri, N.D., Goshtasbi, N., Yuan, J., et al. Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol 36 (2012), 438–443.
41. Taki, K., Takayama, F., Niwa, T., Beneficial effects of Bifidobacteria in a gastro resistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr 15 (2005), 77–80.
42. Hyun, H.S., Paik, K.H., Cho, H.Y., p-Cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis. Korean J Pediatr 56 (2013), 159–164.
43. Urben, L.M., Wiedmar, J., Boettcher, E., Cavallazzi, R., Martindale, R.G., McClave, S.A., Bugs or drugs: are probiotics safe for use in the critically ill?. Curr Gastroenterol Rep, 16, 2014, 388.
44. Hempel, S., Newberry, S., Ruelaz, A., et al. Safety of Probiotics Used to Reduce Risk and Prevent or Treat Disease. 2011, Agency for Healthcare Research and Quality, Rockville, MD, 200.
45. Borges, N.A., Farage, N.E., Barros, A.F., Ferreira, D.C., Fouque, D., Mafra, D., Synbiotic supplementation promotes improvement of chronic diarrhea of unknown etiology in patient with chronic kidney disease and provides better outcomes in dialysis. Nutr Hosp 33 (2016), 182–184.
46. Moraes, C., Borges, N.A., Mafra, D., Resistant starch for modulation of gut microbiota: promising adjuvant therapy for chronic kidney disease patients?. Eur J Nutr 55 (2016), 1813–1821.
47. Esgalhado, M., Borges, N.A., Mafra, D., Could physical exercise help modulate the gut microbiota in chronic kidney disease?. Future Microbiol 11 (2016), 699–707.